NO972729L - Aktivering in vivo av tumorspesifikke cytotoksiske T-celler - Google Patents
Aktivering in vivo av tumorspesifikke cytotoksiske T-cellerInfo
- Publication number
- NO972729L NO972729L NO972729A NO972729A NO972729L NO 972729 L NO972729 L NO 972729L NO 972729 A NO972729 A NO 972729A NO 972729 A NO972729 A NO 972729A NO 972729 L NO972729 L NO 972729L
- Authority
- NO
- Norway
- Prior art keywords
- tumor
- cells
- specific cytotoxic
- vivo activation
- vivo
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
- A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35555894A | 1994-12-14 | 1994-12-14 | |
PCT/US1995/016415 WO1996018409A1 (en) | 1994-12-14 | 1995-12-14 | In vivo activation of tumor-specific cytotoxic t cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NO972729D0 NO972729D0 (no) | 1997-06-13 |
NO972729L true NO972729L (no) | 1997-08-13 |
Family
ID=23397879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO972729A NO972729L (no) | 1994-12-14 | 1997-06-13 | Aktivering in vivo av tumorspesifikke cytotoksiske T-celler |
Country Status (8)
Country | Link |
---|---|
US (1) | US7402314B2 (ja) |
EP (1) | EP0793501A4 (ja) |
JP (1) | JPH10510988A (ja) |
AU (1) | AU712441B2 (ja) |
CA (1) | CA2207736A1 (ja) |
FI (1) | FI972514A (ja) |
NO (1) | NO972729L (ja) |
WO (1) | WO1996018409A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP1767542B1 (en) * | 1996-03-21 | 2016-05-11 | Epimmune Inc. | HLA-A2.1 binding peptides and their uses |
DE69733352T2 (de) * | 1996-03-21 | 2006-04-27 | Epimmune, Inc., San Diego | Hla-a2.1 bindende peptide und deren verwendung |
NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
DE69940774D1 (de) * | 1998-06-17 | 2009-06-04 | Idm Pharma Inc | Hla-bindende peptide und ihre verwendungen |
CA2345440A1 (en) * | 1998-10-05 | 2000-04-13 | Charles A. Nicolette | Genes differentially expressed in cancer cells to design cancer vaccines |
US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
AU5226201A (en) | 2000-04-13 | 2001-10-30 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
ES2394293T3 (es) * | 2001-02-28 | 2013-01-30 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Vacuna contra cánceres que están asociados con el oncogén HER-2/neu |
AU2002316190B8 (en) * | 2001-06-05 | 2009-01-29 | Altor Bioscience Corporation | p53 binding T cell receptor molecules and uses thereof |
CA2522812C (en) | 2003-04-18 | 2012-08-21 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
US20050048646A1 (en) * | 2003-08-25 | 2005-03-03 | Medinet Co., Ltd. | Method for inducing cytotoxic T lymphocyte |
US20080199484A1 (en) * | 2003-10-06 | 2008-08-21 | Cedars-Sinai Medical Center | Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy |
JP5015601B2 (ja) | 2003-10-21 | 2012-08-29 | セダーズ−シナイ メディカル センター | 中枢神経系の癌を含む癌の処置のための系および方法 |
WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
WO2008039974A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
PT2162149E (pt) | 2007-06-01 | 2014-02-12 | Jackson H M Found Military Med | Vacina para a prevenção da recaída do cancro da mama |
EP2250189A4 (en) * | 2008-02-26 | 2012-07-04 | Univ California | GYLCOPEPTIDES AND METHOD FOR THEIR PREPARATION AND USE |
WO2010028066A2 (en) | 2008-09-02 | 2010-03-11 | Cedars-Sinai Medical Center | Cd133 epitopes |
ES2618573T3 (es) | 2009-05-07 | 2017-06-21 | ImmunoCellular Therapeutics,Ltd | Epítopos de CD133 |
US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
EP2608799B1 (en) | 2010-08-24 | 2018-12-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
US10258676B2 (en) * | 2011-09-06 | 2019-04-16 | Agency For Science, Technology And Research | Polypeptide vaccine |
PL3536334T3 (pl) | 2012-05-16 | 2021-12-06 | Stemline Therapeutics Inc. | Szczepionki przeciw rakowi ukierunkowane na komórki macierzyste raka |
EP2956544B1 (en) | 2013-02-14 | 2017-11-01 | Immunocellular Therapeutics Ltd. | Cancer vaccines and vaccination methods |
CN104513293A (zh) * | 2013-09-26 | 2015-04-15 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 |
KR102437995B1 (ko) * | 2016-03-07 | 2022-08-29 | 에프. 호프만-라 로슈 아게 | 항-p53 항체의 검출 |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950598A (en) * | 1982-09-22 | 1990-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Process for making T cell hybridomas |
US5434247A (en) * | 1986-10-10 | 1995-07-18 | Board Of Regents, The University Of Texas System | Peptides for inducing monocyte cytotoxicity in diagnostics |
US5112948A (en) * | 1986-10-10 | 1992-05-12 | Jones C Michael | Methods and compositions for inducing monocyte cytotoxicity |
US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
CA2136624A1 (en) | 1992-05-26 | 1993-12-09 | Cornelis J. M. Melief | Peptides of human p53 protein for use in human t cell response inducing compositions, and human p53 protein-specific cytotoxic t-lymphocytes |
AU4998993A (en) * | 1992-08-07 | 1994-03-03 | Epimmune, Inc. | Hla binding peptides and their uses |
FR2698367B1 (fr) * | 1992-11-02 | 1995-02-17 | Eurobio Lab | Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques. |
KR960700739A (ko) * | 1993-03-05 | 1996-02-24 | 카린 이스텀 | Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses) |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
-
1995
- 1995-12-14 JP JP8519293A patent/JPH10510988A/ja not_active Ceased
- 1995-12-14 AU AU46007/96A patent/AU712441B2/en not_active Expired
- 1995-12-14 WO PCT/US1995/016415 patent/WO1996018409A1/en not_active Application Discontinuation
- 1995-12-14 CA CA002207736A patent/CA2207736A1/en not_active Abandoned
- 1995-12-14 EP EP95944127A patent/EP0793501A4/en not_active Withdrawn
-
1997
- 1997-06-13 FI FI972514A patent/FI972514A/fi not_active IP Right Cessation
- 1997-06-13 NO NO972729A patent/NO972729L/no not_active Application Discontinuation
-
1999
- 1999-03-26 US US09/277,064 patent/US7402314B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH10510988A (ja) | 1998-10-27 |
US7402314B2 (en) | 2008-07-22 |
FI972514A0 (fi) | 1997-06-13 |
CA2207736A1 (en) | 1996-06-20 |
NO972729D0 (no) | 1997-06-13 |
AU4600796A (en) | 1996-07-03 |
AU712441B2 (en) | 1999-11-04 |
WO1996018409A1 (en) | 1996-06-20 |
EP0793501A4 (en) | 2000-05-03 |
EP0793501A1 (en) | 1997-09-10 |
US20030064916A1 (en) | 2003-04-03 |
FI972514A (fi) | 1997-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO972729L (no) | Aktivering in vivo av tumorspesifikke cytotoksiske T-celler | |
NO963738L (no) | Koordinert in vivo-genekspresjon | |
AU9681498A (en) | Chromophores in the preparation of novel tandem conjugates | |
BR9801632A (pt) | Preparação apresentando tolerabilidade aumentada in vivo | |
ATE236607T1 (de) | Herstellung stellen-spezifischer polyethylenglycol-grf konjugate | |
HUP0000474A3 (en) | Arylethenesulfonamide derivatives and drug composition containing the same | |
DE69506901D1 (de) | Körperpflegemittel | |
AU7612196A (en) | Functional human hematopoietic cells | |
ZA9810130B (en) | Tumor-specific antigens methods for their production and their use for imunization and diagnosis | |
IL131319A0 (en) | 3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same | |
DE69831489D1 (de) | Körperpflegemittel | |
PL337277A1 (en) | Body care composition | |
IS5504A (is) | Samsetning virk við meðhöndlun á getuleysi | |
IL126476A0 (en) | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents | |
AU9303398A (en) | The use of natural oils in hot melt adhesives | |
AU1592099A (en) | Skin care composition | |
HK1029928A1 (en) | Pharmaceutical compositions of peptides having lowsolubility in physiological medium. | |
HUP9800635A3 (en) | Medicinal combination useful for in vivo exogenic transfection and expression | |
GB9725946D0 (en) | Lipid compositions and their use | |
AU1524095A (en) | Ex vivo activation of immune cells | |
HUP0000987A3 (en) | Substituted isoquinoline derivatives and their use as anticonvulsants | |
ZA9810687B (en) | Thioglycerol derivatives and their use in polysulfide compositions for optical material | |
AU7915391A (en) | In vivo targeting with bifunctional antibodies | |
IL114228A0 (en) | s-Triazinylaminostilbene derivatives and their use as optical whitening agents | |
AU5844796A (en) | Fused benzodiazepinone derivatives and medicinal composition of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |